Anthony T. Murphy
Research Subjects
Anthony T. Murphy has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Bradley L. Ackermann
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
1 shared publication- Brian G. Lake
A Concept Life Sciences (formerly CXR Biosciences Ltd.) , Dundee , UK
1 shared publication J. R. Bernstein
Department of Drug Metabolism and Disposition, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
1 shared publicationJeffrey L. Holsapple
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
1 shared publicationMichael J. Berna
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
1 shared publication- Ronald B. Franklin
Department of Drug Metabolism, Merck Research Laboratories, Rahway, New Jersey, USA
1 shared publication
Latest Publications
- 4 February 2002
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 16 (6) , 537-543
Effects of flow rate on high‐throughput quantitative analysis of protein‐precipitated plasma using liquid chromatography/tandem mass spectrometry
The effects of flow rate and column length on analyte response (peak area and height), total cycle time, column backpressure, and elution volume are presented. Rapid chromatographic separations and tandem mass spectrometric (MS/MS) detection are applied to the supernatant of protein‐precipitated plasma standards containing four compounds from a drug discovery screen. The plasma samples were injected onto three C‐18 columns (2 × 10,2.1 × 30 and 2.1 × 50 mm) at flow rates of 0.25, 0.50, 1.00 and 1.50 mL/min. The plasma samples were detected using a Sciex API 3000 tandem mass spectrometer operated in the Turbo Ionspray mode. A post‐column split was used to maintain a flow rate of 0.25 mL/min into the mass spectrometer source to avoid differences in nebulization efficiency. The data show that diluted protein‐precipitated plasma supernatants show average matrix effects (i.e. suppression) of 60.0% (2 × 10 mm), 89.3% (2 × 30 mm), and 76.7% (2 × 50 mm) of expected response at 10 ng/mL. Average matrix effects of 70.2% (2 × 10 mm), 88.9% (2 × 30 mm), and 81.2% (2 × 50 mm) of expected response at 1000 ng/mL plasma. The data also show if peak widths remain relatively constant, analytes are less sensitive as flow rates are increased. These data are consistent with the concentration‐dependent relationship of ionspray in the range of flow rates studied. The data show that, while analyte response decreased proportionately to increases in flow rate, the analysis cycle times did not decrease proportionately. Copyright © 2002 John Wiley & Sons, Ltd.
- 4 February 2002
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 16 (6) , 537-543
Effects of flow rate on high‐throughput quantitative analysis of protein‐precipitated plasma using liquid chromatography/tandem mass spectrometry
The effects of flow rate and column length on analyte response (peak area and height), total cycle time, column backpressure, and elution volume are presented. Rapid chromatographic separations and tandem mass spectrometric (MS/MS) detection are applied to the supernatant of protein‐precipitated plasma standards containing four compounds from a drug discovery screen. The plasma samples were injected onto three C‐18 columns (2 × 10,2.1 × 30 and 2.1 × 50 mm) at flow rates of 0.25, 0.50, 1.00 and 1.50 mL/min. The plasma samples were detected using a Sciex API 3000 tandem mass spectrometer operated in the Turbo Ionspray mode. A post‐column split was used to maintain a flow rate of 0.25 mL/min into the mass spectrometer source to avoid differences in nebulization efficiency. The data show that diluted protein‐precipitated plasma supernatants show average matrix effects (i.e. suppression) of 60.0% (2 × 10 mm), 89.3% (2 × 30 mm), and 76.7% (2 × 50 mm) of expected response at 10 ng/mL. Average matrix effects of 70.2% (2 × 10 mm), 88.9% (2 × 30 mm), and 81.2% (2 × 50 mm) of expected response at 1000 ng/mL plasma. The data also show if peak widths remain relatively constant, analytes are less sensitive as flow rates are increased. These data are consistent with the concentration‐dependent relationship of ionspray in the range of flow rates studied. The data show that, while analyte response decreased proportionately to increases in flow rate, the analysis cycle times did not decrease proportionately. Copyright © 2002 John Wiley & Sons, Ltd.
- 1 December 1998
- Published by Wiley in Journal of Mass Spectrometry
- Vol. 33 (12) , 1237-1245
Characterization of olanzapine (LY170053) in human liver slices by liquid chromatography/tandem mass spectrometry
Olanzapine metabolism was investigated using incubation of olanzapine with human liver slices. The intent of the investigation was to identify olanzapine metabolites and determine if the human liver slice incubations could potentially produce quantities of the olanzapine glucuronides for future studies. Along with known Phase 1 olanzapine metabolites, N‐desmethyl‐, 2‐hydroxymethyl‐, and 4′‐N‐oxide‐, a new hydroxylated species was detected. Detection of Phase 2 metabolites included known N‐10‐glucuronides, a quaternary glucuronide and a novel glucuronide conjugate. This investigation showed the feasibility of using human liver slices to produce sufficient quantities of olanzapine glucuronides for further studies. © 1998 John Wiley & Sons, Ltd.
- 1 December 1998
- Published by Wiley in Journal of Mass Spectrometry
- Vol. 33 (12) , 1237-1245
Characterization of olanzapine (LY170053) in human liver slices by liquid chromatography/tandem mass spectrometry
Olanzapine metabolism was investigated using incubation of olanzapine with human liver slices. The intent of the investigation was to identify olanzapine metabolites and determine if the human liver slice incubations could potentially produce quantities of the olanzapine glucuronides for future studies. Along with known Phase 1 olanzapine metabolites, N‐desmethyl‐, 2‐hydroxymethyl‐, and 4′‐N‐oxide‐, a new hydroxylated species was detected. Detection of Phase 2 metabolites included known N‐10‐glucuronides, a quaternary glucuronide and a novel glucuronide conjugate. This investigation showed the feasibility of using human liver slices to produce sufficient quantities of olanzapine glucuronides for further studies. © 1998 John Wiley & Sons, Ltd.